This is what happens when you stop taking Ozempic
Dr. Jen Ashton - ABC News chief medical correspondent
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For This is what happens when you stop taking Ozempic, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "This is what happens when you stop taking Ozempic" from Good Morning America. We read the clip as a GLP-1 Side Effects & Safety claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Studies show people regain about two-thirds of lost weight within a year of stopping semaglutide
The reason this review is not generic is the source wording and the canonical claim label "glp1 side effects this is what happens when you stop taking ozempic." In this clip, the useful excerpt is: "5." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Studies show people regain about two-thirds of lost weight within a year of stopping semaglutide
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video is useful as a prompt for better questions, but it should not be treated as a personalized treatment plan.
- Studies show people regain about two-thirds of lost weight within a year of stopping semaglutide
- Weight regain happens because the biological drivers of obesity (hunger hormones, metabolic adaptation) return when the drug stops
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Studies show people regain about two-thirds of lost weight within a year of stopping semaglutide
- Weight regain happens because the biological drivers of obesity (hunger hormones, metabolic adaptation) return when the drug stops
- Health benefits like improved cardiovascular markers and insulin sensitivity can persist even with partial weight regain
- Many doctors now frame GLP-1 therapy as a long-term or lifetime treatment, similar to blood pressure medication
- Gradual tapering, resistance training, and dietary changes during treatment improve outcomes if you do stop
- People who treated GLP-1s as one tool in a broader lifestyle strategy retained the most weight loss
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What Really Happens When You Stop Ozempic
This is the Ozempic video that 5.5 million people watched. And the reason is obvious: everyone on a GLP-1 drug, or thinking about starting one, has the same question in the back of their mind. What happens when I stop?
Good Morning America covered this with Dr. Jen Ashton, and the answer is straightforward but uncomfortable. Most people regain a significant portion of the weight they lost. The data on this is consistent and hard to argue with.
The Numbers Are Blunt
Research published after the STEP 1 trial extension showed that participants who stopped semaglutide after 68 weeks regained about two-thirds of the weight they had lost within a year of discontinuation. That is not a fringe finding. It has been replicated across multiple studies and is consistent with what clinicians see in practice.
Some people regain all of it. Some regain more than they lost. A smaller group manages to keep a meaningful portion off, typically those who made significant lifestyle changes during treatment and maintained them after stopping.
Dr. Ashton does not sugarcoat this, and that is what makes the segment valuable. There is no magic maintenance phase where your body "locks in" the new weight just because you were on the drug for a year or two.
Why the Weight Comes Back
Your body has a set point. Or more accurately, it has a defended range. When you lose a large amount of weight, your metabolism adjusts. Hunger hormones increase. Energy expenditure decreases. Your body actively works to return to its previous state. This is not a character flaw. It is biology.
GLP-1 drugs override these signals while you are taking them. They suppress appetite through brain receptors, slow gastric emptying, and improve insulin sensitivity. The moment the drug leaves your system, those overrides disappear. Your hunger returns. Your metabolism is still adjusted downward from the weight loss. The deck is stacked toward regain.
This is the same reason why most diets fail long-term. The difference is that GLP-1 drugs are much more effective at producing weight loss in the first place, so the rebound is from a lower starting point and the total regain is larger in absolute terms.
So Is Ozempic Pointless If You Cannot Stay on It Forever?
No. And this is where the conversation needs to shift. The GMA segment touches on it, but the point deserves more emphasis. There are meaningful health benefits that occur during the period of weight loss, even if some weight is regained later.
Cardiovascular risk factors improve. Insulin sensitivity improves. Joint stress decreases. Sleep apnea can resolve. Fatty liver disease can reverse. Some of these improvements have lasting effects even if weight partially rebounds, particularly if you do not return all the way to your starting weight.
There is also the "platform" argument that some endocrinologists make. If you use the period of GLP-1-assisted weight loss to build exercise habits, improve your diet, and address behavioral patterns around food, you may not keep all the weight off, but you may keep more off than you would have without those changes. The drug buys you time to build a foundation.
The Real Question: Is This a Lifetime Medication?
For many people, the honest answer is yes. Just like blood pressure medication or statins, GLP-1 drugs may need to be taken indefinitely to maintain their effect. The medical community is increasingly framing obesity as a chronic disease that requires ongoing treatment, not a condition you fix once and walk away from.
That framing is controversial. It means long-term drug costs, long-term side effect exposure, and dependence on pharmaceutical supply chains. It also means accepting that for many people, the biological drivers of obesity do not go away just because you spent a year at a lower weight.
The GMA segment does not fully resolve this tension, and that is honest. Nobody can tell you definitively whether you should plan to take Ozempic for the rest of your life. That decision depends on your health profile, your risk factors, your insurance coverage, and your values.
Strategies That Help If You Do Stop
Dr. Ashton briefly covers some practical strategies for people who choose to or need to discontinue GLP-1 therapy. Gradual tapering rather than abrupt cessation. Continuing structured exercise, especially resistance training to preserve muscle mass. Working with a dietitian to build sustainable eating patterns before stopping the drug, not after.
The people who maintain the most weight loss after stopping tend to be those who treated the drug as one tool in a larger strategy, not the entire strategy. If Ozempic was your only intervention, and you changed nothing else about your lifestyle, the regain is likely to be severe.
Common Reasons People Stop (and What to Do About Each)
The GMA segment frames stopping as a choice, but in practice, people discontinue GLP-1 drugs for a range of reasons, and not all of them are voluntary. Insurance coverage changes or runs out. The drug goes on backorder and you cannot get your refill. Side effects become intolerable at higher doses. Or a life event, like surgery, pregnancy, or a new medication, makes continuation unsafe. Each of these scenarios calls for a different response. Insurance loss or supply disruption: talk to your prescriber about compounded alternatives or switching to a different GLP-1 drug with better availability. Intolerable side effects: ask about dose reduction rather than full discontinuation, since even a lower dose provides some appetite suppression. Pregnancy or surgery: plan the taper in advance with your doctor rather than stopping cold turkey. Having a contingency plan before you need one is the difference between a managed transition and an uncontrolled rebound.
What the Research Actually Says About Partial Regain
The STEP 1 extension data gets cited a lot, and for good reason. But there is a detail most coverage leaves out. Participants who regained weight after stopping semaglutide did not all return to the same metabolic starting point. Some retained meaningful improvements in HbA1c, blood pressure, and lipid profiles even after partial weight regain. A 2023 analysis in Diabetes, Obesity and Metabolism found that people who kept off even 5% of their original body weight after discontinuation still showed better fasting glucose and triglyceride levels than baseline.
This matters because it reframes the "failure" narrative. Regaining 40 of 60 lost pounds feels like defeat. But if your blood pressure dropped from Stage 2 hypertension to normal range and stayed there, that is a real win, even if your pants size went back up. The conversation around stopping GLP-1 drugs tends to focus entirely on the scale. The metabolic picture is more encouraging than the weight numbers suggest.
Questions to Ask Your Doctor Before Stopping
If you are considering discontinuing a GLP-1 medication, or if your circumstances are forcing the decision, having a specific conversation with your prescriber can make the difference between a managed transition and an uncontrolled spiral. Here are the questions that matter most:
1. Should I taper my dose down gradually, or is stopping abruptly acceptable for my situation?
2. What bloodwork should we check before and after discontinuation to track metabolic changes?
3. Is there a lower maintenance dose that could preserve some benefit without the full cost or side effect burden?
4. Should I switch to a different GLP-1 receptor agonist if cost or supply is the issue?
5. What is a realistic weight regain range I should expect, and at what point should I call your office?
6. Can you refer me to a registered dietitian to build a post-medication nutrition plan before I stop?
7. Are there any medications I stopped because of GLP-1 effects (like blood pressure or diabetes drugs) that I might need to restart?
These are not hypothetical questions. They are the ones that endocrinologists and obesity medicine specialists say patients almost never ask, and the ones that lead to the best outcomes when they do.
How This Compares to Other GLP-1 Discontinuation Content
The FormBlends library has several other videos that touch on what happens during and after GLP-1 therapy. The Ozempic Butt video with Dr. Dustin Portela covers the physical skin and body changes that happen with rapid weight loss, which directly connects to the post-discontinuation experience since regaining weight after skin has already loosened creates a different set of problems than the original weight gain did. The Dr. Craig Koniver episode on peptide and hormone therapies discusses GLP-1 medications as part of a broader protocol, and his take is relevant here: Koniver emphasizes that patients who build a multi-layered approach (sleep optimization, resistance training, hormone balance) before stopping any single intervention tend to hold onto more of their gains.
What the GMA segment does better than most is keep it simple. Dr. Ashton is talking to a general audience, not a biohacking crowd. She sticks to the core message: the weight will probably come back if you stop, and you need a plan. That directness is why 5.5 million people watched. Sometimes the most useful health content is the version that does not overcomplicate things.
The Real-World Math of Long-Term GLP-1 Use
One thing the GMA segment only touches on briefly is cost, and it deserves a harder look. Brand-name semaglutide runs roughly $900 to $1,350 per month without insurance in 2026. Even with insurance, copays often land between $25 and $300 per month depending on your plan. Over a decade of continuous use, you are looking at tens of thousands of dollars. Compounded versions have been cheaper when available, but their regulatory status keeps shifting (the Brigham Buhler JRE episodes in the FormBlends library cover that situation in detail).
The financial reality forces a practical question: if you cannot afford indefinite treatment, when is the best time to stop? Obesity medicine specialists generally say that the longer you maintain the lower weight before discontinuing, the better your chances of retaining some of the loss. Stopping after six months produces worse long-term outcomes than stopping after two years. Your body has more time to establish new patterns around appetite, activity, and metabolic function. It is not a guarantee, but it tips the odds in your favor. If you know your insurance is changing or your budget is tightening, talk to your doctor now, not the week your last refill runs out.
Why 5.5 Million People Watched This
Because it answers the question nobody wants to ask their doctor. Is this permanent? And the answer, for most people, is no. Not unless you keep taking it or fundamentally change how you live. That is not a reason to avoid GLP-1 drugs. But it is a reason to go in with realistic expectations and a plan for what comes next.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Good Morning America · Dr. Jen Ashton - ABC News chief medical correspondent
5.5M views on this video
5.5M views - massive mainstream reach
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about studies show people regain about two-thirds of lost weight within?
Studies show people regain about two-thirds of lost weight within a year of stopping semaglutide
What does the video say about weight regain happens?
Weight regain happens because the biological drivers of obesity (hunger hormones, metabolic adaptation) return when the drug stops
What does the video say about health benefits like improved cardiovascular markers?
Health benefits like improved cardiovascular markers and insulin sensitivity can persist even with partial weight regain
What does the video say about many doctors now frame glp-1 therapy as a long-term?
Many doctors now frame GLP-1 therapy as a long-term or lifetime treatment, similar to blood pressure medication
What does the video say about gradual tapering, resistance training,?
Gradual tapering, resistance training, and dietary changes during treatment improve outcomes if you do stop
What does the video say about people who treated glp-1s as one tool in a broader?
People who treated GLP-1s as one tool in a broader lifestyle strategy retained the most weight loss
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Good Morning America, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.